24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Epidemiology and burden of HPV-related disease.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Human papillomavirus (HPV) infection is recognized as one of the major causes of infection-related cancer in both men and women. High-risk HPV types are not only responsible for virtually all cervical cancer cases but also for a fraction of cancers of the vulva, vagina, penis, anus, and head and neck cancers. Furthermore, HPV is also the cause of anogenital warts and recurrent respiratory papillomatosis. Despite the availability of multiple preventative strategies, HPV-related cancer remains a leading cause of morbi-mortality in many parts of the world, particularly in less developed countries. Thus, in this review, we summarize the latest estimates of the global burden of HPV-related diseases, trends, the attributable fraction by HPV types, and the potential preventative fraction.

          Related collections

          Author and article information

          Journal
          Best Pract Res Clin Obstet Gynaecol
          Best practice & research. Clinical obstetrics & gynaecology
          Elsevier BV
          1532-1932
          1521-6934
          Feb 2018
          : 47
          Affiliations
          [1 ] Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme (CERP), Institut Català d'Oncologia (ICO) - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Electronic address: bscarro@iconcologia.net.
          [2 ] Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme (CERP), Institut Català d'Oncologia (ICO) - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Electronic address: mbrotons@idibell.cat.
          [3 ] Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme (CERP), Institut Català d'Oncologia (ICO) - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Electronic address: x.bosch@iconcologia.net.
          [4 ] Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme (CERP), Institut Català d'Oncologia (ICO) - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Electronic address: lbruni@iconcologia.net.
          Article
          S1521-6934(17)30124-4
          10.1016/j.bpobgyn.2017.08.006
          29037457
          47296f46-4371-49c7-8b71-1f3f8cd39543
          History

          Prevention,Time trends,Human papillomavirus,Attributable fraction,Papillomavirus vaccines,Cancer

          Comments

          Comment on this article